Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Cat-PAD in Cat-Allergic Paediatric Subjects
2014-000279-15Phase 2Completed
- Sponsor
- NIOX Group
- Start
- May 2014
- Modality
- Vaccines & Immunotherapeutics, Peptides
- Countries
- 1
01
Overview
Phase 2, single-blind trial of Cat-PAD in cat allergy, allergic rhinoconjunctivitis (ARC) and perennial rhinitis (2 arms), sponsored by NIOX Group. Primary endpoint: Safety: proportion and frequency of adverse events and local injection site reactions. Started May 2014; status: completed.
02
Drugs
Cat-PAD
03
Conditions
cat allergyallergic rhinoconjunctivitis (ARC)perennial rhinitis
Beyond the preview
Go deeper on 2014-000279-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-000279-15.